Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Gains from Investment Securities (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Gains from Investment Securities for 5 consecutive years, with $9.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 167.84% year-over-year to $9.6 million, compared with a TTM value of $7.7 million through Dec 2025, down 3.08%, and an annual FY2025 reading of $7.7 million, down 31.51% over the prior year.
  • Gains from Investment Securities was $9.6 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $143000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $9.6 million in Q4 2025 and bottomed at -$6.5 million in Q4 2023.
  • Average Gains from Investment Securities over 5 years is $665100.0, with a median of $325500.0 recorded in 2021.
  • Peak annual rise in Gains from Investment Securities hit 6875.0% in 2022, while the deepest fall reached 1292.64% in 2022.
  • Year by year, Gains from Investment Securities stood at $420000.0 in 2021, then tumbled by 982.62% to -$3.7 million in 2022, then crashed by 76.1% to -$6.5 million in 2023, then surged by 154.69% to $3.6 million in 2024, then surged by 167.84% to $9.6 million in 2025.
  • Business Quant data shows Gains from Investment Securities for KNSA at $9.6 million in Q4 2025, $143000.0 in Q3 2025, and $70000.0 in Q2 2025.